COMP <GO>
SBC vs JNJ // FREE CASH FLOW YIELD
SBC Medical Group Holdings Incorporated (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: SBC 7
— JNJ 5
▲ FREE CASH FLOW YIELD LEADER: SBC
LAST: $5.69 (+4.40%) • MKT CAP: $585.2M
fcf-yield
3.98%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
fcf-yield
2.97%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SBC VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SBC | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 73.30% | 67.90% | +5.40 | SBC | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 63.10% | 25.50% | +37.60 | SBC | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.1x | 18.5x | -12.40 | SBC | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 3.98% | 2.97% | +1.01 | SBC | /fcf-yield <GO> |
| Operating Margin | 38.90% | 34.70% | +4.20 | SBC | /operating-margins <GO> |
| Net Profit Margin | 29.40% | 28.50% | +0.90 | SBC | /net-margins <GO> |
| Revenue Growth (YoY) | -15.50% | 6.00% | -21.50 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.46 | 5.59 | -0.13 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.6 | 62.1 | -2.50 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.7x | 23.0x | -12.30 | SBC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $585.2M | $662.49B | -$661.91B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SBC REV | JNJ REV | SBC GROSS % | JNJ GROSS % | SBC FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $173.6M | $94.19B | 73.3% | 67.9% | $23.3M | $19.70B |
| FY 2024 | $205.4M | $88.82B | 76.0% | 69.1% | $18.0M | $19.84B |
| FY 2023 | $193.5M | $85.16B | — | — | $50.7M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SBC // BETA —
JNJ // BETA 1.08